[go: up one dir, main page]

FR2718150B1 - Virus recombinants, préparation et utilisation en thérapie génique. - Google Patents

Virus recombinants, préparation et utilisation en thérapie génique.

Info

Publication number
FR2718150B1
FR2718150B1 FR9403682A FR9403682A FR2718150B1 FR 2718150 B1 FR2718150 B1 FR 2718150B1 FR 9403682 A FR9403682 A FR 9403682A FR 9403682 A FR9403682 A FR 9403682A FR 2718150 B1 FR2718150 B1 FR 2718150B1
Authority
FR
France
Prior art keywords
preparation
gene therapy
recombinant viruses
viruses
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9403682A
Other languages
English (en)
Other versions
FR2718150A1 (fr
Inventor
Marc Abitbol
Jacques Mallet
Michel Perricaudet
Frederic Revah
Paul Roustan
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Rhone Poulenc Rorer SA
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9403682A priority Critical patent/FR2718150B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Rhone Poulenc Rorer SA, Institut Gustave Roussy (IGR) filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU21425/95A priority patent/AU2142595A/en
Priority to CA002184755A priority patent/CA2184755A1/fr
Priority to PCT/FR1995/000374 priority patent/WO1995026409A1/fr
Priority to US08/718,482 priority patent/US6685934B1/en
Priority to EP95914419A priority patent/EP0753067A1/fr
Priority to JP7525005A priority patent/JPH09510621A/ja
Priority to IL11315295A priority patent/IL113152A0/xx
Priority to ZA952563A priority patent/ZA952563B/xx
Publication of FR2718150A1 publication Critical patent/FR2718150A1/fr
Application granted granted Critical
Publication of FR2718150B1 publication Critical patent/FR2718150B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9403682A 1994-03-29 1994-03-29 Virus recombinants, préparation et utilisation en thérapie génique. Expired - Fee Related FR2718150B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR9403682A FR2718150B1 (fr) 1994-03-29 1994-03-29 Virus recombinants, préparation et utilisation en thérapie génique.
CA002184755A CA2184755A1 (fr) 1994-03-29 1995-03-24 Adenovirus recombinants codant pour les facteurs de croissance des fibroblastes basiques (bfgf)
PCT/FR1995/000374 WO1995026409A1 (fr) 1994-03-29 1995-03-24 ADENOVIRUS RECOMBINANTS CODANT POUR LES FACTEURS DE CROISSANCE DES FIBROBLASTES BASIQUES (bFGF)
US08/718,482 US6685934B1 (en) 1994-03-29 1995-03-24 Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)
AU21425/95A AU2142595A (en) 1994-03-29 1995-03-24 Recombinant adenoviruses coding for basic fibroblast growth factors (bfgf)
EP95914419A EP0753067A1 (fr) 1994-03-29 1995-03-24 ADENOVIRUS RECOMBINANTS CODANT POUR LES FACTEURS DE CROISSANCE DES FIBROBLASTES BASIQUES (bFGF)
JP7525005A JPH09510621A (ja) 1994-03-29 1995-03-24 塩基性繊維芽細胞増殖因子（ｂＦＧＦ）をコードする組換えアデノウイルス
IL11315295A IL113152A0 (en) 1994-03-29 1995-03-27 Recombinant adenoviruses encoding fibroblast growth factors their preparation and their use in gene therapy
ZA952563A ZA952563B (en) 1994-03-29 1995-03-29 Recombinant viruses their preparation and their use in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403682A FR2718150B1 (fr) 1994-03-29 1994-03-29 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (2)

Publication Number Publication Date
FR2718150A1 FR2718150A1 (fr) 1995-10-06
FR2718150B1 true FR2718150B1 (fr) 1996-04-26

Family

ID=9461540

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9403682A Expired - Fee Related FR2718150B1 (fr) 1994-03-29 1994-03-29 Virus recombinants, préparation et utilisation en thérapie génique.

Country Status (9)

Country Link
US (1) US6685934B1 (fr)
EP (1) EP0753067A1 (fr)
JP (1) JPH09510621A (fr)
AU (1) AU2142595A (fr)
CA (1) CA2184755A1 (fr)
FR (1) FR2718150B1 (fr)
IL (1) IL113152A0 (fr)
WO (1) WO1995026409A1 (fr)
ZA (1) ZA952563B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
CN100569297C (zh) 1995-02-28 2009-12-16 加利福尼亚大学董事会 基因转移介导的血管形成疗法
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US20020164313A1 (en) * 1995-03-16 2002-11-07 Tremblay Jacques P. Compositions comprising preconditioned myoblasts having enhanced fusion properties
US6183993B1 (en) 1996-09-11 2001-02-06 The General Hospital Corporation Complement-resistant non-mammalian DNA viruses and uses thereof
AU4266597A (en) 1996-09-11 1998-04-14 General Hospital Corporation, The Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
CA2264966A1 (fr) 1996-09-11 1998-03-19 The General Hospital Corporation Virus a adn non mammalien qui possede une proteine de coque modifiee
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
JP2002539176A (ja) * 1999-03-15 2002-11-19 カイロン コーポレイション 眼の疾患を処置または予防するための組換え遺伝子送達ベクターの使用
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
AU2001295193A1 (en) * 2000-05-01 2001-11-12 Novartis Ag Vectors for ocular transduction and use thereof for genetic therapy
EP1170373A1 (fr) * 2000-07-03 2002-01-09 Retina France Transfection des cellules de l'oeil médiée par des peptides
BR0306925A (pt) * 2002-01-18 2004-11-09 Schering Ag Formulações estabilizadas de adenovìrus
WO2004047727A2 (fr) * 2002-11-01 2004-06-10 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procedes pour diagnostiquer et traiter des troubles de l'humeur
EP1766077B1 (fr) * 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
AU2006315562C1 (en) 2005-11-12 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating depression using NCAM peptide mimetics
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2014198003A1 (fr) 2013-06-14 2014-12-18 Ottawa Hospital Research Institute Compositions et procédés pour améliorer l'efficacité d'un virus
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
BR112017018846A2 (pt) 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439818A (en) * 1985-09-12 1995-08-08 Scios Nova Inc. DNA encoding human recombinant basic fibroblast growth factor
US4816339A (en) * 1987-04-28 1989-03-28 Baxter International Inc. Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0582796A1 (fr) * 1992-06-01 1994-02-16 Takeda Chemical Industries, Ltd. Promoteur pour l'expression et son utilisation
DE69334238D1 (de) * 1992-09-25 2008-09-25 Aventis Pharma Sa Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn
CA2149771A1 (fr) 1992-11-18 1994-05-26 Jeffrey M. Leiden Transfert de genes dans le muscle lisse des vaisseaux et du coeur effectue par l'intermediaire d'adenovirus
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
EP0753067A1 (fr) 1997-01-15
ZA952563B (en) 1995-12-21
AU2142595A (en) 1995-10-17
US6685934B1 (en) 2004-02-03
FR2718150A1 (fr) 1995-10-06
CA2184755A1 (fr) 1995-10-05
WO1995026409A1 (fr) 1995-10-05
JPH09510621A (ja) 1997-10-28
IL113152A0 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
DK0595436T3 (da) Porcint respirations- og reproduktionssygdomsvirus, vacciner og viralt dna
EP0710667A3 (fr) Oligonucléotides modifiés, leur préparation et leur utilisation
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
FI962990A7 (fi) Menetelmä rekombinanttisten adenovirukseen assosioituvien virusten (AA V:iden) valmistamiseksi ja sen käyttöjä
AU3824595A (en) Recombinant negative strand RNA virus expression systems and vaccines
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
FI955154A7 (fi) Viruskombinantteja ja niiden käyttö geeniterapiassa
AU2328397A (en) Recombinant live feline immunodeficiency virus and proviral dna vaccines
AU1927797A (en) Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
NO971495L (no) Svekkede virus og fremgangsmåte til deres fremstilling
CA2278808A1 (fr) Procedes pour la culture de cellules et la multiplication de virus
OA09664A (en) Virus/herbicide-resistance genes, processes for the preparation thereof and the use thereof
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
FR2717496B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO902248L (no) Renininhiberende peptider, deres fremstilling og anvendelse i legemidler.
FR2726575B1 (fr) Virus recombinants, preparation et utilisation en therapie genique

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20061130